Legal & General Group
CDTX

Legal & General Group’s Cidara Therapeutics CDTX Stock Holding History

Legal & General Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,460
Closed -$2.31M – 3372
2025
Q4 		$2.31M Sell
10,460
-1,005
-9% -$162K ﹤0.01% 1911
2025
Q3 		$1.1M Buy
11,465
+9,965
+664% +$636K ﹤0.01% 2214
2025
Q2 		$72.9K Buy
+1,500
New +$36K ﹤0.01% 2667
2021
Q2 		– Sell
-197
Closed -$10K – 3513
2021
Q1 		$10K Hold
197
– – ﹤0.01% 3371
2020
Q4 		$8K Hold
197
– – ﹤0.01% 3385
2020
Q3 		$11K Sell
197
-64
-25% -$4.52K ﹤0.01% 3189
2020
Q2 		$19K Buy
+261
New +$16.9K ﹤0.01% 3081
2017
Q2 		– Sell
-74
Closed -$12K – 3359
2017
Q1 		$12K Hold
74
– – ﹤0.01% 3167
2016
Q4 		$15K Buy
+74
New +$15.4K ﹤0.01% 3159

Legal & General Group's CDTX Position: Q1 2026 in Review

Legal & General Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 10,460 shares — an estimated $2.31M sold.

Legal & General Group first reported a position in CDTX in Q4 2016 and held it in 9 quarters. The position peaked at $2.31M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Legal & General Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Legal & General Group sold 10,460 Cidara Therapeutics shares in Q1 2026, an estimated $2.31M.
  • Legal & General Group first reported a position in Cidara Therapeutics in Q4 2016 and held it in 9 quarters.
  • Legal & General Group's Cidara Therapeutics position peaked at $2.31M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.